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Surface Plasmon resonanceShort Linear Motifs (SLiMs) are functional protein microdomains that typically mediate interactions
between a short linear region in one protein and a globular domain in another. Surface Plasmon
Resonance assays have been performed to determine the binding affinity between PDZ domain of wild
type human PALS1 protein and tetradecapeptides representing the SLiMs sequences of SARS-CoV-1
and SARS-CoV-2 E proteins (E-SLiMs). SARS-CoV-2 E-SLiM binds to the human target protein with a
higher affinity compared to SARS-CoV-1, showing a difference significantly greater than previously
reported using the F318W mutant of PALS1 protein and shorter target peptides. Moreover, molecular
dynamics simulations have provided clear evidence of the structural determinants driving this binding
process. Specifically, the Arginine 69 residue in the SARS-CoV-2 E-SLiM is the key residue able to both
enhance the specific polar interaction with negatively charged pockets of the PALS1 PDZ domain and
reduce significantly the mobility of the viral peptide. These experimental and computational data are
reinforced by the comparison of the interaction between the PALS1 PDZ domain with the natural ligand
CRB1, as well as the corresponding E-SLiMs of other coronavirus members such as MERS and OCF43. Our
results provide a model at the molecular level of the strategies used to mimic the endogenous SLiM pep-
tide in the binding of the tight junctions of the host cell, explaining one of the possible reasons of the
severity of the infection and pulmonary inflammation by SARS-CoV-2.
 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the first report on the scientific literature of the Severe
and Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) at
Wuhan at the end of 2019 which triggered the current pandemic
[1], the scientific community started an intense and focused study
onto the mechanism driving the transmission and the virulence ofthis new pathogen [2–5]. In particular due to the genomic similar-
ity with SARS-CoV-1 appeared in 2002 and 2003, a special atten-
tion was reserved to the comparison of the two viruses in term
of their ability to infect the host human cells of the respiratory
tract [6–8]. After more than one year, some elements emerged
from this common effort as expected due to genomic similarity
[5]. As a first clear evidence, both the virus SARS-CoV-1 and
SARS-CoV-2 viruses enter in the human cells utilizing the
angiotensin-converting enzyme 2 receptor (ACE2) [9,10]. Accord-
ingly, the spike proteins (S) of the two viruses were analysed and
their efficiency in formation of the active complex with ACE2
receptor was deeply investigated. A large set of experimental and
computational studies were focused onto the clarification of the
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interaction, as a possible explanation for the pandemic event all
over the globe caused by SARS-CoV-2, but not by SARS-CoV-1
[11–17]. These studies were also stimulated by the possible conse-
quences, in term of a structure-based drug design of small mole-
cules able to interfere with the process of virus entering in the
host cells, to be used in clinic practice as specific antiviral com-
pounds [18,19].
A second set of structural studies focused their attention onto
the main viral enzymes. On one hand there is the protease
(Mpro, also called 3CLpro) because of its essential role in processing
the polyproteins that are translated from the viral RNA. Still in the
case of this topic, a strong stimulus for researchers was the idea to
find a possible antiviral compound to target this enzyme, thus
helping the clinicians in their dramatic effort to cope with the
multifaceted syndrome that SARS-CoV 2 is producing in patients
[20–23]. On the other hand, there is the RNA dependent RNA
Polymerase enzyme (RdRP) due to its critical role in the mecha-
nism of viral genome production, that has been also intensively
studied as a potential target for selective antiviral compounds
[24–27]. In both cases, structural differences and functional
properties of these enzymes, among different members of the
Coronaviridae family, have been compared to investigate a possible
better catalytic efficiency of these key enzymes as a cause of the
virus spread [28].
The last protein target that was also studied from a structural
point of view, is the Envelope protein (E). The E protein is directly
involved in the mechanism of virus infection due to the presence in
its primary structure of Short Linear Motifs (also known as SLiMs)
that are responsible of protein–protein interaction with the tight
junction of the host cell, via the formation of a complex with the
PDZ domain of the human PALS1 protein [29,30]. This protein
has been suggested playing a central role in the virulence of
SARS-CoV-1 as demonstrated by Castaño-Rodriguez and coworkers
that clearly showed in mice models that a virus lacking of the PDZ
binding motif in the E protein, drastically reduced its replication
and virulence [31].
In a previous paper [32], we provided a first model to explain a
strengthened binding of SARS-CoV-2 E protein with the tight
junction-associated PALS1, with respect to the SARS-CoV-1 by in
silico analysis and docking studies. This work was performed using
a SLiM octapeptide for both SARS-CoVs which represents the min-
imal unit identified for protein–protein interaction. At the same
time, a 3-fold higher affinity for the SARS-CoV-2 peptide with
respect to SARS-CoV-1 was experimentally measured by Toto
et al, using a mutant of the human PALS1 protein (F318W) through
equilibrium and ultra-fast kinetic binding measurements moni-
tored by FRET [33], thus giving experimental support to our in silico
model. The F318W mutant was selected for the FRET measure-
ments due to the higher intrinsic fluorescence of the variant
expressing tryptophan. Nevertheless, the topological position 318
of PALS1 in our model, was considered interacting with both the
target viral peptides. Thus, in the present study, we compare the
binding affinities to the SARS-CoV peptides of both the wild type
and the F318Wmutant PALS1 by using Surface Plasmon Resonance
(SPR). We also elongated the interacting viral peptides to 14 resi-
dues each, in the experimental determination as well as in molec-
ular dynamics simulations. This choice was a compromise: in fact,
on one hand computational studies identify the length of a SLiM
sequence in the range of 3–12 residues, therefore the length of
14 residues should be sufficient to take into consideration all the
main structural determinants driving the binding process medi-
ated by this protein motifs [34]. On the other hand, the 3D struc-
ture of the human PDZ domain of PALS1 in complex with its
endogenous targeting peptide CRB1 was made of 17 residues, but
only 14 were reported in the model, due to high mobility of the last1839ones [35]. Therefore, in the present study, we set the length of all
peptides considered as potential target of the human PDZ PALS1
to 14 residues, as reported in the Supplementary Fig. 1.2. Results and discussion
2.1. Surface Plasmon resonance (SPR) measurements of binding
affinity
N-terminal biotinylated version of the three C-terminal tetrade-
capeptides, the endogenous PALS1 ligand CRB1 (MWNLMPPPA-
MERLI) and the envelope E protein derived peptides of SARS-
CoV-1 (KNLNSSEGVPDLLV) and SARS-CoV-2 (VKNLNSSRVPDLLV)
were immobilized on different streptavidin chips and used as
ligands in a SPR assay. As analytes, PDZ domains of PALS1, both
wild-type and F318W variant, were used. The PALS1 mutant was
previously used by Toto et al., to measure the Kd values of the
interaction with a shorter version of the same SARS-CoV-2 and
SARS-CoV-1 envelope E protein peptides [33]. These authors, using
as a probe the intrinsic fluorescence of the Trp introduced in the
topological position 318 of the PALS1 protein, obtained a Kd = 40
± 10 and a Kd = 130 ± 10 lM respectively, for SARS-CoV-2 and
SARS-CoV-1 E-SLiMs peptides.
According to SPR measurements, the affinities for PALS1 F318W
mutant of the longer viral tetradecapeptides used in this assay, are
in good agreement with what previously reported for the shorter
ones with a different experimental technique. Specifically, the Kd
value measured for SARS-CoV-2 was Kd = 29 ± 4 lM while the
value for SARS-CoV-1 was Kd = 69 ± 7 lM (see Table 1 and Scatch-
ard plot in Fig. 1A and 1B). In both cases the Kd values were slightly
lower than the values previously measured, possibly due to the
longer peptides used that may have a larger interaction surface
with the PALS1 target mutant protein, thus enhancing the binding
affinity. As shown in Fig. 1C and reported in Table 1, the endoge-
nous CRB1 peptide presented a higher affinity with a lower Kd
value that is 18 ± 2 lM.
Next, we measured the affinities of these same peptides to
PALS1 wild-type protein domain. The Kd trend among the three
peptides remains unchanged, having always the endogenous pep-
tide CRB1 the lowest Kd = 5.11 ± 0.33 lM (see Table 1 and Fig. 1 E)
which is comparable to that previously measured by Ivanova, et al.,
that is Kd = 9.2 ± 1.4 lM [35]. Moreover, SARS-CoV-2 peptide has
still a lower Kd value with respect to SARS-CoV-1 even if, using
the wild-type protein as a target in the SPR assay, the difference
in binding affinity between the two viral peptides drastically
increased. Indeed, the SARS-CoV-2 peptide Kd value was = 63 ± 10
lM (see Table 1 and Scatchard plot in Fig. 1D) while the SARS-CoV-
1 peptide Kd value can be only considered having a lower limit of
500 lM. In fact, its binding isotherm maintains linear-like beha-
viour in the PALS1 concentration range measured (see Fig. 1E)
therefore a larger experimental error is associated to this measure
(see Table 1). This very weak affinity could seem hardly sufficient
to be detected by co-immunoprecipitation (Co-IP), yet it was ini-
tially identified using this same technique [30]. However, it has
to be noted that Co-IP in vitro experiments probed the interaction
between the full-length Envelope protein and PALS1 PDZ domain
and not just the E-SLiM peptide as in the present study. Accord-
ingly, a further contribution of the entire Envelope could be suffi-
cient to allow detection of this protein complex using Co-IP. This
fact may be expected considering that, using the endogenous bind-
ing protein Crb-CT, the larger complex PALS1-PDZ-SH3-GK but not
the isolated PDZ domain, binds it with very high affinity [36]. On
the other hand, Teoh and coworkers clearly demonstrate that the
minimal unit necessary to trigger the interaction between E pro-
tein and PDZ-PALS1 involves specifically the E-SLiM peptide [30].
Fig. 1. Scatchard plots of the interactions between immobilized tetradecapeptides and the analytes, PALS1 F318W and PALS1 wild-type at T = 25 C. Triangles represent
experimental data points and solid lines are the fit. Data point were obtained at the following concentration [PALS1_F318W] = 120, 60, 15, 7.5, 3.75 and 1.875 lM and
[PALS1_wt] = 60, 30, 15, 7.5, 3.75 and 1.875 lM. Panel A, binding isotherm of PALS1 F318 W and SARS-CoV-2 E peptide. B, binding isotherm of PALS1 F318 W and SARS-CoV-1
E peptide, C, binding isotherm of of PALS1 F318W variant and CRB1, D, binding isotherm of PALS1 wild type and SARS-CoV-2 E peptide E, binding isotherm of PALS1 F318W
variant and SARS-CoV-1 E peptide, F, binding isotherm of PALS1 wild type and CRB1 peptide.
Table 1
Kd values obtained by the SPR measurements.
SARS-CoV-2 SARS-CoV-1 CRB1
PALS 1 F318 W 29 ± 4 lM 69 ± 7 lM 18 ± 2 lM
PALS 1 Wild type 63 ± 10 lM > 500 lM 5.11 ± 0.33 lM
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has a higher affinity for both the viral peptides (but not for the
endogenous peptide CRB1) with respect to wild type PALS1 pro-
tein, suggests a direct involvement of this residue into the binding
mechanism of the viral peptides. As reported in our previous paper
[32], where a docking of the two viral peptides is reported and
compared with the crystal structure of the wild type protein in
complex with CRB1, F318 is one of the key residues inside the
PDZ domain, involved in the stabilization of the interaction
between the last four residues of the peptides that form the Protein
Binding Motif (PBM). In fact, according to the docking model, F318
interacts with the third residue in the PBM, starting from the C-
terminus, which is an Arginine (R1404 see Fig. S1) for CRB1 and
a Leucine (L74 and L73 see Fig. S1) for both SARS-CoVs peptides.
Accordingly, its substitution with a bulkier side chain, as the Trp
residue, may have an impact onto the binding affinity.
2.2. Molecular dynamics simulations
In order to better understand the differences of the affinities
measured between the viral peptides and the wild-type and
mutated PALS1 proteins, molecular dynamics was used to investi-
gate the conformational variability of the two proteins. At first, two
500 ns long molecular dynamic simulations of both PALS1 wild-
type and F318W mutant alone were performed. To point out the
difference between these two MD simulations we have reported
in Fig. 2, panels A and B the chi1-chi2 side-chain torsion angle1840combinations for residue 318, along the whole trajectory. In this
graph the open circle colour depends on the distance between cen-
ter of mass (c.o.m.) of the side chain selected (both F or W) and c.o.
m. of residue L321 that is placed in the bottom-center of the bind-
ing groove of PALS1. As shown in Fig. 2 panel A, F318 in PALS1
wild-type protein is a very flexible residue, with many possible ori-
entations that are highly distributed. Moreover, considering the
distance of 7 Å from the residue L321, discriminant between open
and closed conformation, the different orientations of the angles
for Phe are equally distributed between these two states, therefore
all the clusters in panel A contain both green and purple circles
equally represented.
On the contrary, a Tryptophan residue in the same position has
a more restrained and defined dynamic behaviour, as W318 con-
formations are less disperse (see Fig. 2 panel B). In fact, its confor-
mations distribute in just three different and clearly marked
clusters that according to the relative distance between the c.o.m
of W318 and L321 define an open and a closed conformation. In
this case, one cluster is formed exclusively by a single set of green
dots representing the conformations where PALS1 groove is clearly
open (with a distance to L321 > 7 Å); while the other two clusters
are made only of purple dots, outlining the conformations that lead
to a closed state of the protein (with a distance to L321 < 7 Å). The
sum of the purple dots, representing the closed conformation, is
much more represented (about 80%) along the whole trajectory,
thus indicating a preferential position for this residue in this con-
formation. In Fig. 2, panels C and D, we show the protein structures
of PALS1, with the two alternative positions (open in green, closed
in purple), for the residues in the topological position 318. These
positions where selected according to a clustering of the corre-
sponding conformations of Panel A and B, selecting as open state
for Phe, the position that this residue has in the crystal structure
bound to CRB1, while for the closed one, the position that is closer
to the protein groove. On the other hand, the lower mobility of Trp
Fig. 2. Molecular Dynamics simulation of the free PALS1 wild type and F318W variant. Panels A and B show the chi1-chi2 side-chain torsion angle combinations for residue
318, obtained by 500 ns long molecular dynamics simulations of the two PALS1 variants, where dot colour depends on the distance between center of mass (c.o.m.) of the side
chain and c.o.m. of L321 (in red) placed in the bottom-center of the binding groove of PALS1. A, Wild type protein. B, F318W protein. C the 3D model of PALS1 wild type,
showing two different conformation of F318 that are equally populated during the simulation. In purple the closed position of F318 in green the open one, D, the 3D model of
PALS1 F318W variant showing the two different conformation of W318, keeping the same color code of panel C. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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that this residue can slip into the hydrophobic pocket stabilizing
PALS1 in a closed state, potentially hindering the binding pocket
available for all the peptides. This model suggests a lower affinity
of PALS1 F318W for peptides binding in the internal groove, if
the affinity change is simply driven by a reduction in the on-rate
of formation of the active complex, and could explain the three-
fold higher value of CRB1 Kd for PALS1 F318W compared to the
wild type protein. Nevertheless, this model would be in contrast
with the experimental data showing a higher affinity of the mutant
of PALS1 for both the viral peptides. In the absence of a kinetic
determination of the kon and koff rate constants in the SPR mea-
surements, the higher affinity of the PALS1 mutant with respect
to the wild type protein, for the viral peptides, but not for CRB1,
suggests that the Trp318 residue is able to better interact with
these viral peptides stabilizing them in the bound state.
In order to verify this hypothesis a second set of MD simulations
was performed. Starting from the reported 3D structure of the
complex wild-type PALS1 and CRB1 peptide, three different com-
putational models were prepared (see Materials and Methods sec-
tion for detailed information on the molecular docking
procedures): a) PALS1 F318W in complex with SARS-CoV-2 E-
SLiM, b) PALS1 F318W in complex with SARS-CoV-1 E-SLiM and
c) PALS1 F318W in complex with CRB1 SLiM. At least two MD runs
of 500 ns each were done for any model; the simulations were
analysed considering only the last 300 ns of each simulation and
concatenating them. Results in term of the interaction established
along this trajectory are reported in Fig. 3 panels A-C for the corre-
sponding models. Noticeably, the complex PALS1 F318W - SARS-
CoV-1 E-SLiM was run three times, as the peptide was not stable
along the entire simulation in at least two over three cases. There-1841fore, for this system, data refer only to the last 300 ns of the more
stable MD simulation. Panels D-F of the same picture show the
most representative structures obtained after a clustering of the
MD runs (see pie chart at the bottom of the picture) as purple pep-
tides, while in white it is reported the starting configuration
obtained after the initial docking procedure.
As expected, the interaction of the W318 was clearly evident in
all the three systems analysed being the large bulky side chain able
to interact with all the three peptides. Moreover, looking at the
other interaction that are formed, it is also evident that the two
viral peptides share a similar interaction pattern, with a significant
reinforcement of the polar interaction of SARS-CoV-2 E-SLiM with
K261 and R282 with respect to SARS-CoV-1 E-SLiM. On the con-
trary the endogenous CRB1 SLiM shows an important difference
in the interaction pattern as due to the arginine residue R1404, that
is able to form a strong interaction with the protein couple aspar-
agine N315 and W318. This special condition is due to the fact that
this polar residue protrudes in the direction of the two aminoacids
as shown in Fig. 3 panel F.
Finally, to clarify the structural determinants driving the bind-
ing mechanism that identify SARS-CoV-2 E-SLiM as a better ligand
with respect to SARS-CoV-1 E-SLiM for the wild type PALS1 pro-
tein, three further different computational models were built-up
starting from the 3D structure of the complex wild-type PALS1
and CRB1 SLiM. A set of 500 ns long simulations, 2 for CRB1
SLiM-PALS1 complex, and 4 for both SARS-CoVs tetradecapeptides,
were made and only the last 300 ns of each simulation were anal-
ysed in term of the interaction established along the simulations.
About SARS-CoV-2 MD simulations, only one was not used in the
analysis due to peptide detachment from PALS1 before the end of
the simulation. On the contrary, data for SARS-CoV-1 are not
Fig. 3. A, B, C Interaction histograms of SARS-CoV-2, SARS-CoV-1 and CRB1 E-SLiM peptides against PALS1 F318Wmutant. Results include hydrophobic and polar contacts, h-
bonds, salt bridges and p-cation as derived analyzing the last 300 ns of two 500 ns long molecular dynamics for each complex. D, E, F) Most representative conformations of
SARS-CoV-2, SARS-CoV-1 and CRB1 are reported in purple, where only the last 8 residues are shown, in complex with PALS1 F318W. The structures superimposed in white,
represent the starting conformations coinciding with the structure obtained via docking procedure for SARS-CoV-2 and SARS-CoV-1, while the minimized crystallographic
conformation for CRB1 is reported (PDB code: 4UU5, after mutation F318 ? W318). The pie charts below every structural representation show the distribution of peptide
conformations obtained through clustering. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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remain attached to PALS1 > 150–200 ns. In order to verify if the
stability of the PALS1 E-SLiM complex was characteristic only of
SARS-CoV-2 E peptide, two other models were prepared, using as
a ligand to the human protein the corresponding E-SLiMs tetrade-
capeptides of two other members of the Coronaviridae family,
MERS and OC43 (see Fig. S1). The complex formed by OC43-E-
SLiM and wild type PALS1 PDZ domain was highly unstable detach-
ing from the human protein in less than 50 ns in 4 different MD
runs (data not shown). On the contrary, the complex MERS-E-
SLiM with wild type PALS1 protein, was highly stable in both the
500 ns MD runs, thus allowing to analyse the binding poses and
report them in Fig. 4 together with SARS-CoV-2 and CRB1.
Despite sharing the same binding site, CRB1 and viral tetrade-
capeptides interact differently with their target. The SARS-COV-2
E-SLiM achieves to slip deeply in the groove of PALS1, indeed,
the negatively charged carboxylic group of the C-terminus Valine
V75 residue can reach both R263 and K261, making with them salt
bridge interactions and polar contacts (as shown in Fig. 4 panel A).
As a consequence, the C-terminal V75 side-chain interacts with
hydrophobic residues of PALS1 domain deep in the pocket, inter-
acting with L321, G326 and F330. Among the cited PALS1 residues,
only K261 is reached by CRB1 C-terminal carboxylic group of Iso-
leucine I1406, as this peptide is strongly anchored in its initial
position from this bulkier residue that is not able to get deeper
in the groove as the corresponding Valine V75 of the SARS-COV-2
E-SLiM. The MERS-E-SLiM peptide has also a Valine C-terminal
residue (V82 see Fig. S1), but it is not able to slip deeply as the
other viral peptide, due to the different anchoring points to the
human PALS1 protein in the following residues. Specifically,
SARS-COV-2, MERS and CRB1 share a hydrophobic residue in the
second position from the C-terminus (L74, W81 and L1405 for
SARS-CoV-2, MERS and CRB1 respectively) while the third one is1842totally different. For CRB1 SLiM, there is a positively charged resi-
due (R1404), while an other hydrophobic one (L73) is present for
SARS-CoV-2 E-SLiM and a negatively charged one (E80) is present
for MERS E-SLiM. As can be seen in Fig. 4, the CRB1 SLiM Arginine
R1404 makes both hydrophobic and pi-cation interactions with
F318 and polar contact and H-bonds with N315 of PDZ PALS1
domain. By contrast, SARS-CoV-2 E-SLiM Leucine L73 can only
interact hydrophobically with F318, with negligeable interactions
with N315. Also MERS E-SLiM E80 interact only hydrophobically
with F318 using the aliphatic carbons of the side chain having neg-
ligeable interactions with N315. This last viral peptide though, uses
the W81 to strongly interact with R282, via a pi-cation interaction
thus enhancing its stability in the binding groove. Finally, consid-
ering the last residue of the PBM, CRB1 SLiM Glutamate E1403
interacts via salt bridge with R282 and R272 and has a polar inter-
action with T270. The arginine R282 in the human protein target, is
harder to be reached by the shorter Aspartate D72 of SARS-CoV-2
E-SLiM, that achieves to interact only with R272. On the contrary,
the D79 of MERS-E-SLiM is able to chelate R282 due to the com-
bined action with W81 that fix the Arginine residue of PALS1 in
the suitable position (see Fig. 4 for detailed information).
In our previous article [32], by molecular docking, we showed
that SARS-CoV-2 E-SLiM Arginine R69 was able to form a salt
bridge with aspartate D313. Unexpectedly, R69 does not interact
with this residue significantly along the MD trajectory, but still
maintains a central role in the binding mechanism. In facts, com-
pared to the conformation obtained by molecular docking, which
is the initial conformation of the simulation (white in Fig. 4 panel
D), the backbone of the peptide straightens, moving away the resi-
due from its starting point and finding a larger negative pocket in
which stably lying. In fact, as shown in Fig. 4 panel D, SARS-CoV-2
E-SLiM Arginine R69 swings and finds other negatively charged
residues, such as E274 and D276, as well as may form polar con-
Fig. 4. A, B, C Interaction histograms of SARS-CoV-2, MERS and CRB1 E-SLiM peptides against PALS1 wild-type. Results include hydrophobic and polar contacts, h-bonds, salt
bridges, p-cation as derived analyzing the last 300 ns of two 500 ns long molecular dynamics for each complex. D, E, F) Most representative conformations of SARS-CoV-2,
MERS and CRB1 are reported in purple, where only the last 8 residues are shown, in complex with PALS1 wild-type. The structures superimposed in white represent the
starting conformations, coinciding with the structure obtained via docking procedure for SARS-CoV-2 and MERS, while the crystallographic conformation is reported for CRB1
(PDB code: 4UU5). The pie charts below every structural representation show the distribution of peptide conformations obtained through clustering. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
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with the residues of PALS1 protein are common for all peptides
and are made in an unspecific mode by peptide backbones.
As a further consideration, SARS-CoV-2 E-SLiM finds 4 charged
residues on PALS1 to anchor on it. As it is shown in Fig. 5, it con-
stantly interacts with K261 and R272, in the C terminus part of
the peptide and is able to find two negative shallow pockets, one
with D276 and the other one with E274, through its Arginine
R69 residue that is exclusive for SARS-CoV-2 peptide, since neither
CRB1 SLiM, nor MERS E-SLiM or even SARS-CoV-1 E-SLiM, have
positively charged residue in the same topological position. In par-
ticular, the endogenous peptide CRB1 has a proline residue in this
position (P1400) followed by two other proline residues that
strongly reduce its freedom degrees thus favouring the interaction
with PALS1 PDZ partner domain. This same strategy is enhanced by
MERS-E-SLiM, that has L76 in the same topological position, in the
middle of four Proline residues (P74, P75, P77 and P78 see Fig. S1)
that strongly stabilizes the Leucine L76 in a bound conformation.
On the contrary, SARS-CoV-1 has a glycine residue (G70) in this
same position, with no proximal proline residues able to reduce
its mobility.
Therefore this topological position seems the key one to explain
the difference in affinity between the SARS-CoVs peptides, due to
the different contribution to the binding with PALS1 between
R69 residue of SARS-CoV-2 and the G70 of SARS-CoV-1. In order
to verify this hypothesis, we reported in Fig. 6 the result of the first
150 ns of Molecular Dynamics simulation obtained for the complex
wild type PALS1 with SARS-CoV-2, SARS-CoV-1 and MERS E-SLiMs
with specific reference to this topological position comparing thew
and u angles of the residues R69, G70 and L76 respectively. This
time range was selected as SARS-CoV-1 E-SLiM still forms a stable
complex with wild-type PALS1 before breaking down.1843As shown in panel A and B of Fig. 6, w and u angles for SARS-
CoV-2 E-SLiM R69 are stable and clustered along the trajectory
explored (see blue traces). The same is true for the MERS- E-SLiM
L76 (green traces). On the contrary, for SARS-CoV-1 E-SLiM G70,
the w angle (panel B), toward the C-terminal head of the peptide
remains relatively stable with occasional flipping episodes, mean-
while the rotation on SARS-CoV-1 u angle is much higher (panel A),
flipping constantly and creating high instability to the N-terminal
portion of the peptide, thus leading to the breakdown of the
complex.
3. Conclusion
Our first aim was to compare the binding affinity of the SLiM
sequences of the viral Envelope proteins of SARS-CoV-1 and
SARS-CoV-2 to their protein target in the tight junction of the
epithelial human cells, that is the PDZ domain of PALS1. The direct
measurement of the binding affinity of both viral E-SLiMs with
respect to the wild type PDZ domain of PALS1, allowed to deter-
mine a Kd value of 63 lM for SARS-CoV-2 and only a lower limit
of 500 lM for SARS-CoV-1, with a difference between them close
to a factor 10. Previous results underestimated this difference,
measuring Kd values that were only three-fold lower for the
SARS-CoV-2 E-SLiM with respect to SARS-CoV-1 (Kd value of
40 lM with respect to 130 lM).
The main reason of this discrepancy is probably the use in pre-
vious work of the F318Wmutant of PALS1, instead of the wild-type
protein, as we have demonstrated that the Trp substituent is
actively perturbing the mechanism of interaction with the viral
peptides, being less crucial for the CRB1 bindingmechanism. More-
over, using smaller peptides the entropic effect due to SLiM resi-
dues farther from the binding groove is missing.
Fig. 5. Surface of PALS1. In blue are shown side chains of positively charged residues, in red negatively charged residues and in green the non polar residues. Arrows indicate
the different anchor points used by SARS-CoV-2 E SLiM. Blue arrows point in the direction of K261 and R272. Red arrows point in the direction of the negative charged pockets
identified by residues D276 and E274. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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the MD simulations for the complex with wild type PALS1 protein.
Indeed, the SARS-CoV-1 did not remain stably bound for a com-
plete set of 500 ns simulation time, due to the significant difference
that this peptide exhibits in the topological position where it has
the highly mobile glycine residue (G70) that is not able to fix this
peptide into the right position, thus allowing its release from
PALS1. On the contrary, in SARS-CoV-2 this glycine is substituted
by the positively charge residue of Arginine (R69), that anchors sta-
bly the peptide to the target human protein interacting with shal-
lows negatively binding pockets, reducing the mobility of the
whole peptide thus enhancing its binding affinity. The CRB1
endogenous ligand has a 3 proline motifs (P1398-P1400) that
strongly reduce the mobility of the whole SLiM peptide, thus
favouring a more stable interaction with its protein PALS1 partner.
This same strategy is used by MERS-E SLiM peptide, where we
observe a similar motif (PPLPP), centered to the L76 residue that
corresponds to the same topological position of R69 and G70 in
SARS-CoV2 and SARS-CoV-1 respectively.
In conclusion, according to the combined in silico study and SPR
assay, we have been able to point out the structural determinants
that allow SARS-COV-2 E-SLiM to interact with a significantly
higher affinity with respect to SARS-COV-1 E-SLiM to the PALS1
wild type protein.4. Materials and methods
4.1. Protein expression and purification
Gene encoding for the PDZ domain of PALS1 was subcloned in a
pET-28b (+) plasmid vector which was used to transform Escheri-
chia coli cells BL21 (DE3) strain. Bacterial cells were grown in LB
medium, containing 30 lg/mL of kanamycin, at 37 C until
OD600 = 0.8–0.9 was reached. Protein expression was induced with
1 mM IPTG. After induction, cells were incubated at 25 C over-
night and then collected by centrifugation. Bacterial pellet was
resuspended in buffer Tris-HCl 50 mM, NaCl 0.3 M, pH 7.5 with
the addition of antiprotease tablet (Complete EDTA-free, Roche),
then sonicated and centrifuged. The soluble fraction from bacterial
lysate was loaded onto a nickel-charged HisTrap Chelating HP (GE1844Healthcare) column equilibrated with Tris-HCl 50 mM, NaCl 0.3 M,
imidazole 10 mM, pH 7.5. Protein was then eluted with a gradient
from 0 to 1 M Imidazole by using an ÄKTA-prime system. Fractions
containing the protein were identified through SDS-page and col-
lected. The imidazole present in the sample was removed by using
a HiTrap Desalting column (GE Healthcare) equilibrated in Tris-HCl
50 mM, NaCl 0.3 M, pH7.5. The purity of the protein was analyzed
through SDS-page.
F318W variant of the PDZ domain of PALS1 was obtained by
site-directed mutagenesis using a QuickChange Lightning Site-
Directed Mutagenesis kit (Agilent Technologies), accordingly to
the instructions of the manufacturer. The variant was expressed
and purified following the same protocol used for the wild-type.
4.2. Surface Plasmon resonance measurements
The interactions between the peptides (ligands) and the puri-
fied PALS1 PDZ domains, both wild type and F318W mutant (ana-
lytes) were measured by surface Plasmon resonance (SPR)
technique using a Biacore X100 instrument (Biacore, Uppsala, Swe-
den). The N-terminal biotinylated peptides were obtained from
GenScript (Piscataway, NJ, USA) and were immobilized on a Sensor
Chip SA, precoated with streptavidin from Biacore AB (Uppsala,
Sweden). Capturing procedure on biosensor surface was performed
according to manufacturer’s instructions. Running buffer was PBS,
which contains 10 mM phosphate buffer pH 7.4, 0.137 M NaCl,
2.7 mM KCl. Protein domains were diluted in running buffer, and
binding experiments were performed at 25 C with a flow rate of
30 ll/min. The highest concentration obtained for the wild type
protein was 60 lM while for the mutant F318W was 120 lM.
The concentrations measured in the SPR assay were obtained by
successive dilutions halving the concentration in each step.
The association phase was followed for 180 s, whereas the dis-
sociation phase was followed for 300 s. Each experiment was per-
formed using a minimum of 6 different concentration of the
analyte and the intermediate concentration was repeated twice
to test the reproducibility of data. The regeneration of the surface
was achieved by addition of 2 M NaCl for 30 s before each new
cycle start. When experimental data met quality criteria, data were
analysed using Biacore X100 Evaluation Software. An affinity
steady state model was applied to fit the data, as kinetic parame-
Fig. 6. Comparison of u/w angles of the residue in the same topological position of SARS-CoV-2, SARS-CoV-1 and MERS E-SLiM peptides: Variation of the angles are obtained
analyzing the first 150 ns of molecular dynamic simulation of peptides-PALS1 wild-type complexes. Panel A, comparison of u angles of SARS-CoV-2 R69 (in blue), SARS-CoV-1
G70 (in red) and MERS L76 in green. Panel B, comparison of w angles of same residues. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
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equilibrium signal of interaction was clearly detected. Accordingly,
specific Kd were determined with a confidence interval associated
with a standard error value.
4.3. In silico docking of Envelope tetradecapeptides to PALS1 wild-type
and preparation of the peptides-PALS1 F318W complexes
The fourteen C-terminal residues of each E protein were built,
(see Fig. S1) and protonation states were assigned with PROPKA
[37]. To construct the peptide-protein complexes, the tetrade-
capeptides were manually superimposed and aligned onto the con-
formations of the octapeptides already docked on PALS1, which
were obtained from our previous work [32] or anew docking pro-
cedure was performed. Finally, the complexes were minimized
using Prime [38].1845In order to build the complexes between the peptides and
PALS1 F318W mutant, the F318 residue of every peptide-protein
complex was substituted with a Tryptophan, via Maestro tools,
and the systems were minimized with Prime.
Moreover, in both complexes of CRB1 with PALS1 wild-type and
mutant, CRB1 SME1402, a methionine sulfoxide present in the ref-
erence model (PDB code: 4UU5, [35]), was modified with a
methionine.
4.4. Molecular dynamics simulations
Classical molecular dynamics simulations were performed with
the GROMACS 2018.3 [39] package using the CHARMM36m force-
field [40], with WYF parameter for cation-pi interactions, at the full
atomistic level using a TIP3 water solvent. All the molecular
dynamics sessions were performed in a water system prepared
E. Lo Cascio, A. Toto, G. Babini et al. Computational and Structural Biotechnology Journal 19 (2021) 1838–1847via the CHARMM-GUI server [41]. The protein–ligand systems
were solvated in a cubic water box (having basis vectors lengths
of 7.1 nm) under periodic boundary conditions. The total charge
of the system was neutralized by randomly substituting water
molecules with Na+ ions and Cl– ions, to obtain neutrality with
0.15 M salt concentration.
Following a steepest descent minimization algorithm, the sys-
tem was equilibrated in canonical ensemble (NVT) conditions for
125 ps, using Nose-Hoover thermostat with position restraints
for the protein-peptide complexes. Then, all restraints were
removed, and molecular dynamics runs were performed under
NPT conditions at 303.15 K, using Nose-Hoover thermostat, with
a T-coupling constant of 1 ps, and a Parrinello-Raman barostat at
1 atm. Van der Waals interactions were modelled using 6–12
Lennard-Jones potential with a 1.2 nm cut-off. Long-range electro-
static interactions were calculated, with a cut-off for the real space
term of 1.2 nm. All covalent bonds were constrained using the
LINCS algorithm. The time step employed was 2 fs, and the coordi-
nates were saved every 5 ps for analysis, which was performed
using the standard GROMACS tools.4.5. Analysis of molecular dynamics trajectories
Percentages of formation of hydrogen bonds interactions along
MD trajectories have been calculated by custom procedures using
the MDAnalysis python library [42]. Polar and hydrophobic inter-
actions between peptides and receptor residues were modelled
as average coordination numbers via a continuous, differentiable
switching function:







with the i and j indexes running over the interacting atoms within
the peptide fragment of interest and those within a chosen receptor
residue, with 0  strength  ni nj (where ni and nj are the total num-
ber of atoms of the peptide fragment and the receptor residue,
respectively, able to make the chosen type of interaction). For
hydrophobic interactions, only carbon atoms are considered, for
polar interactions only oxygens and nitrogens. The same ‘‘strength”
function was calculated for salt bridges, p-cation and p-p interac-
tions. In this case ni = nj = 1 because virtual atoms are defined at
the center of mass of aromatic rings or charged groups, hence
0  strength  1. For hydrophobic, salt bridges, p-cation and p-p
interactions a = 6, b = 12 and r0 = 6 Å, 5 Å, 4 Å, 5.5 Å respectively,
while for polar interactions a = 8, b = 12, r0 = 2.5. The chosen values
of r0 account for the typical interaction distance plus thermal
motion’s amplitude (e.g. ~4.5 Å + ~1.5 Å in the case of hydrophobic
interactions). The Plumed package [43] was patched to the Gromacs
engine to undergo this kind of analysis. These coordination num-
bers (one per residue of the binding site) can be calculated on single
structures as well as averaged along trajectories.
Beyond the roughness of the approach used here to monitor p–
p and p-cation interactions (based only on the distances between
c.o.m.), a careful characterization of them would require quantum
mechanics. However, it is known that classical molecular dynamics
using fixed-charge force fields has been successfully applied to
describe p-stacking in both parallel and T-shaped configurations
and p-cation [44–46].4.6. Artwork
3D images of peptide-receptor structures were obtained by the
Chimera software [47].1846Declaration of Competing Interest
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